[1] Kesuma, Y.,Firmansyah, A.,Bardosono, S.,et al.,”Blastocystis ST-1 is associated with Irritable Bowel Syndrome-diarrhoea (IBS-D) in Indonesian adolescences”,Parasite epidemiology and control,2019;6:e00112.doi: 10.1016/j.parepi.2019.e00112.
[2] Sperber AD, Dumitrascu D, Fukudo S,et al.,”The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review”,Gut,2017;66:1075–82.doi: 10.1136/gutjnl-2015-311240.
[3] Lacy BE, Pimentel M, Brenner DM, et al.,”ACG clinical guideline: management of irritable bowel syndrome”,Am J Gastroenterol,2021;116: 17–44.doi: 10.14309/ajg.0000000000001036.
[4] Drossman,D. A., and Hasler, W. L.,”Rome IV-Functional GI Disorders:Disorders of Gut-Brain Interaction”Gastroenterology,2016;150,150(6):1257-61.doi: 10.1053/j.gastro.2016.03.035.
[5] Emanuele Sinagra,Giancarlo Pompei,Giovanni Tomasello,et al.,”Inflammation in irritable bowel syndrome: Myth or new treatment target?”World J. Gastroenterol,2016;22(7):2242-55.doi: 10.3748/wjg.v22.i7.2242.
[6] Nuha Alammar,Ellen Stein,”Irritable Bowel Syndrome.What treatments really work”,Med Clin North Am,2019;103(1):137-152. doi: 10.1016/j.mcna.2018.08.006.
[7] I. W. Deveson, S. A. Hardwick, T. R. Mercer, and J. S. Mattick,“The dimensions, dynamics, and relevance of the mammalian noncoding transcriptome,”Trends in Genetics,2017;33(7):464–478.doi: 10.1016/j.tig.2017.04.004.
[8] B. D. Adams, C. Parsons, L. Walker, W. C. Zhang, and F. J.Slack,“Targeting noncoding RNAs in disease”,Journal of Clinical Investigation, 2017;127(3):761–771.doi: 10.1172/JCI84424.
[9] Hombach, S.; Kretz, M,”Non-coding RNAs: Classification, biology and functioning”,Adv. Exp. Med. Biol,2016;937:3-17.doi: 10.1007/978-3-319-42059-2_1.
[10] Guanqun Chao,Zhaojun Wang,Yi Yang,et al.,"LncRNA H19 as a Competing Endogenous RNA to Regulate AQP Expression in the Intestinal Barrier of IBS-D Patients",Frontiers in physiology,2021;11:602076.doi: 10.3389/fphys.2020.602076.
[11] K Zhao,J-Y Tan,Q-D Mao,et al.,"Overexpression of long non-coding RNA TUG1 alleviates TNF-α-induced inflammatory injury in interstitial cells of Cajal",European review for medical and pharmacological sciences,2019;23(1):312-320.doi: 10.26355/eurrev_201901_16778.
[12] Nicolaas H Fourie,Ralph Michael Peace,Sarah K Abey,et al.,"Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome",Experimental and molecular pathology,2014;96(3):422-5.doi: 10.1016/j.yexmp.2014.04.009.
[13] Swapna Mahurkar-Joshi,Carl Robert Rankin,Elizabeth Jane Videlock,et al.,"The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling",Gastroenterology,2021;160(7):2409-2422.doi: 10.1053/j.gastro.2021.02.040.
[14] Ying Xing,Shan Xue,Jing Wu,et al.,"Serum Exosomes Derived from Irritable Bowel Syndrome Patient Increase Cell Permeability via Regulating miR-148b-5p/RGS2 Signaling in Human Colonic Epithelium Cells",Gastroenterology research and practice,2021;2021:6655900.doi: 10.1155/2021/6655900.
[15] He Zhu,Xiao Xi,Chai Yuna,et al.,"MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7",Biochemical and biophysical research communications,2019;511(3):671-678.doi: 10.1016/j.bbrc.2019.02.126.
[16] Cristina Martínez,Bruno K Rodiño-Janeiro,Beatriz Lobo,et al.,"miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea",Gut,2017;66(9):1537-1538.doi: 10.1136/gutjnl-2016-311477.
[17] He Zhu,Xi Xiao,Yuying Shi,et al.,"Inhibition of miRNA-29a regulates intestinal barrier function in diarrhea-predominant irritable bowel syndrome by upregulating ZO-1 and CLDN1",Experimental and therapeutic medicine,2020;20(6):155.doi: 10.3892/etm.2020.9284.
[18] QiQi Zhou,Liuqing Yang,Scott Larson,et al.,"Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1",Gut,2016;65(5):797-805.doi: 10.1136/gutjnl-2013-306464.
[19] Lixia Pei,Hao Chen,Jing Guo,et al.,"Effect of acupuncture and its influence on visceral hypersensitivity in IBS-D patients: Study protocol for a randomized controlled trial",Medicine,2018;97(21):e10877.doi: 10.1097/MD.0000000000010877.
[20] Marwa A Mansour,Norhan A Sabbah 2,Shymaa A Mansour,et al.,"MicroRNA-199b expression level and coliform count in irritable bowel syndrome",IUBMB life,2016;68(5):335-42.doi: 10.1002/iub.1495.
[21] QiQi Zhou,G Nicholas Verne,"miRNA-based therapies for the irritable bowel syndrome",Expert opinion on biological therapy,2011;11(8):991-5.doi: 10.1517/14712598.2011.577060.
[22] Carolin Wohlfarth,Stefanie Schmitteckert,Janina D Härtle,et al.,"miR-16 and miR-103 impact 5-HT receptor signalling and correlate with symptom profile in irritable bowel syndrome",Scientific reports,2017;7(1):14680.doi: 10.1038/s41598-017-13982-0.
[23] Xiu-Jun Liao,Wei-Ming Mao,Qin Wang,et al.,"MicroRNA-24 inhibits serotonin reuptake transporter expression and aggravates irritable bowel syndrome",Biochemical and biophysical research communications,2016;469(2):288-93.doi: 10.1016/j.bbrc.2015.11.102.
[24] Jing Guo,Gao Lu,Lu Chen,et al.,"Regulation of serum microRNA expression by acupuncture in patients with diarrhea-predominant irritable bowel syndrome",Acupuncture in medicine : journal of the British Medical Acupuncture Society,2021;9645284211027892.doi: 10.1177/09645284211027892.
[25] QiQi Zhou,Wiley W Souba,Carlo M Croce,et al.,"MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome",Gut,2010;59(6):775-84.doi: 10.1136/gut.2009.181834.
[26] Damian Jacenik,Adam I Cygankiewicz 2,Jakub Fichna,et al.,"Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome",Molecular and cellular endocrinology,2018;471:89-96.doi: 10.1016/j.mce.2017.07.036.
[27] Wenhua Tao,Xiaoyun Dong,Guimei Kong,et al.,"Elevated Circulating hsa-miR-106b, hsa-miR-26a, and hsa-miR-29b in Type 2 Diabetes Mellitus with Diarrhea-Predominant Irritable Bowel Syndrome",Gastroenterology research and practice,2016;2016:9256209.doi: 10.1155/2016/9256209.
[28] Yu Zhang,Xiaxin Wu,Jinfeng Wu,et al.,"Decreased expression of microRNA-510 in intestinal tissue contributes to post-infectious irritable bowel syndrome via targeting PRDX1",American journal of translational research,2019;11(12):7385-7397.PMID: 31934286 PMCID: PMC6943457.
[29] Chan Zhang,Ronggan Liang,Xiaowen Gan,et al.,”MicroRNA‑384‑5p/Beclin‑1 as potential indicators for epigallocatechin gallate against cardiomyocytes ischemia reperfusion injury by inhibiting autophagy via PI3K/Akt pathway”,Drug Des Devel Ther,2019;13:3607-3623. doi: 10.2147/DDDT.S219074. eCollection 2019.
[30] Lifeng Fei,Yanjing Wang.”microRNA-495 reduces visceral sensitivity in mice with diarrhea-predominant irritable bowel syndrome through suppression of the PI3K/AKT signaling pathway via PKIB”,IUBMB Life. 2020 Jul;72(7):1468-1480.doi: 10.1002/iub.2270.
[31] Su-Zhen Song,Sen Lin,Jia-Ning Liu,et al.”Targeting of SPP1 by microRNA-340 inhibits gastric cancer cell epithelial-mesenchymal ransition through inhibition of the PI3K/AKT signaling pathway”,Journal of cellular physiology,2019 Aug;234(10):18587-18601. doi: 10.1002/jcp.28497.
[32] Lama Darbelli,Stéphane Richard,”Emerging functions of the Quaking RNA-binding proteins and link to human diseases”,Wiley Interdiscip Rev RNA,2016;7(3):399-412. doi: 10.1002/wrna.1344.
[33] Amy Cochrane,Sophia Kelaini,Marianna Tsifaki,et al.,”Quaking is a key regulator of endothelial cell differentiation,neovascularization, and angiogenesis”,Stem Cells,2017;35(4):952-966. doi: 10.1002/stem.2594.
[34] W Samuel Fagg,Naiyou Liu,Jeffrey Haskell Fair,et al.,”Autogenous cross-regulation of Quaking mRNA processing and translation balances Quaking functions in splicing and translation”,Genes Dev,2017;31(18):1894-1909. doi: 10.1101/gad.302059.117.
[35] Aline Bonnet,Guillaume Lambert,Sylvain Ernest,et al.,”Quaking RNA-binding proteins control early myofibril formation by modulating tropomyosin”,Dev. Cell,2017;42(5):527-541.e4. doi: 10.1016/j.devcel.2017.08.004.
[36] Ji S, Ye G, Zhang J, Wang L, Wang T, Wang Z, et al. miR-574–5p negatively regulates Qki6/7 to impact beta-catenin/Wnt signalling and the development of colorectal cancer. Gut. 2013;62(5): 716–26.doi: 10.1136/gutjnl-2011-301083.
[37] Pengcheng Shu,Hongye Fu,Xiangyu Zhao, et al.,”MicroRNA-214 modulates neural progenitor cell differentiation by targeting quaking during cerebral cortex development”,Sci Rep,2017;7(1):8014.doi: 10.1038/s41598-017-08450-8.
[38] Liang Chu,Yuqin Hu,Ying-Hao Jiang,et al.,”Effects of RNA binding protein QKI on pancreatic cancer ductal epithelial cells and surrounding activation fibroblasts”,Journal of cellular biochemistry,2019 Apr 10. doi: 10.1002/jcb.28435.
[39] Junko Mukohyama,Taichi Isobe,Qingjiang Hu,et al.,”miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells”,Cancer Res,2019;79(20):5151-5158. doi: 10.1158/0008-5472.CAN-18-3544.
[40] Zhang, R. L., Yang, J. P., Peng, L. X.,et al.,”RNA-binding protein QKI-5 inhibits the proliferation of clear cell renal cell carcinoma via post-transcriptional stabilization of RASA1 mRNA”,Cell Cycle,2016;15(22):3094-3104. doi: 10.1080/15384101.2016.1235103.
[41] Binbin Zhang,Maolin Chen,Nan Jiang ,et al.,”A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma”,Cancer Biol Ther,2019;20(8):1127-1135. doi: 10.1080/15384047.2019.1598762.
[42] C David Wood,Hildegonda Veenstra,Sarika Khasnis,et al.,”MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfguration of enhancerpromoter hubs",Elife,2016;5:e18270. doi: 10.7554/eLife.18270.
[43] Weichun Tang,Jie Li,Hongbin Liu,et al.,”MiR-106a promotes tumor growth, migration, and invasion by targeting BCL2L11 in human endometrial adenocarcinoma”,Am J Transl Res. 2017;11(9):4984–93.PMID: 29218096,PMCID: PMC5714782.
[44] Jun Chen,Yang Lin,Yan Jia,et al.,”LncRNA HAND2-AS1 exerts anti-oncogenic effects on ovarian cancer via restoration of BCL2L11 as a sponge of microRNA-340-5p”,J Cell Physiol,2019;234(12):23421–36.doi: 10.1002/jcp.28911.
[45] Zhisen Shen,Xiaoying Chen,Qun Li,et al.,”TGFB2 and BCL2L11 methylation in male laryngeal cancer patients”,Oncol Lett. 2016;12(4):2999–3003.doi: 10.3892/ol.2016.5018.
[46] Qingyun Pan,Ying Huang,Yirui Wang,et al.,”LncRNA ACTA2-AS1 suppress colon adenocarcinoma progression by sponging miR-4428 upregulation BCL2L11”,Cancer Cell Int. 2021 Apr 12;21(1):203. doi: 10.1186/s12935-021-01769-3.
[47] Haiyang Zhang,Jingjing Duan,Yanjun Qu,et al.,”Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer”,Protein Cell. 2016 Feb;7(2):141-51. doi: 10.1007/s13238-015-0234-5.
[48] Yuan Yuan,Xiaoling Li,Yudong Chu,et al.,”Long Non-coding RNA H19 Augments Hypoxia/Reoxygenation-Induced Renal Tubular Epithelial Cell Apoptosis and Injury by the miR-130a/BCL2L11 Pathway”,Front Physiol. 2021 Feb 26;12:632398. doi: 10.3389/fphys.2021.632398.